Revenio Group Oyj - Decisions of general meeting

Revenio Group Corporation: Decisions by the Annual General Meeting

Revenio Group Corporation, Stock Exchange Release, March 22, 2017 at 18:20

Decisions by the Annual General Meeting of Revenio Group Corporation on March
22, 2017

1. Financial statements, Board and Auditors

The AGM confirmed the company's financial statements for the financial year 1
January - 31 December 2016, and discharged the members of the Board of Directors
and the Managing Director from liability.

The AGM decided that five members be elected to the Board of Directors and re-
elected Ari Kohonen, Pekka Rönkä, Kyösti Kakkonen, Ann-Christine Sundell and
Pekka Tammela as board members. In its meeting held after the AGM, the Board of
Directors re-elected Pekka Tammela as Chair of the Board.

The AGM decided that the Chairman of the Board be entitled to an annual
emolument of EUR 48,000 and the other Board members to an annual emolument of
EUR 24,000.

A total of 40 per cent of Board members' emoluments will be settled in the form
of company shares, while 60 per cent will comprise a monetary payment.

The AGM elected Deloitte & Touche Oy, Authorized Public Accountants, as the
company's auditors with Elina Reilander, Authorized Public Accountant, acting as
the principal auditor. The AGM decided to compensate the auditors, upon the
presentation of a reasonable invoice.

2. Annual profit distribution, dividend distribution and capital repayment

The AGM decided to accept the Board's proposal on profit distribution, according
to which the profit for the financial period, EUR 8,099,312.66, will be added to
retained earnings, and a dividend of EUR 0.74 per share will be paid. Dividends
will be paid to shareholders who have been registered in the company's
shareholder register, maintained by Euroclear Finland Ltd, by the dividend
record date on March 24, 2017. The dividend payment date is March 31, 2017.

4. Authorizing the Board of Directors to decide to repurchase the Company's own
shares

The AGM rescinded its earlier authorization to buy back 795,392 of the company's
own shares and authorized the Board to make the decision to buy back a maximum
of 797,940 of the company's own shares in one or several tranches using the
Company's non-restricted equity capital. The Company may buy back shares in
order to develop its capital structure, finance and implement any corporate
acquisitions or other transactions, implement share-based incentive plans, or
otherwise transfer or cancel them.

The Company may buy back shares in public trading on marketplaces whose rules
and regulations allow the Company to trade in its own shares. In such a case,
the Company buys back shares through a directed purchase, that is, in a
proportion other than its shareholders' holdings in Company shares, with the
consideration for the shares based on their publicly quoted market price, in
such a manner that the minimum price of the purchased shares equals the lowest
market price quoted in public trading during the authorization period, and,
similarly, their highest price equals the highest market price quoted in public
trading during that period.

This authorization will be valid until April 30, 2018. This authorization shall
supersede the buyback authorization granted at the AGM of March 15, 2016.

5. Authorizing the Board of Directors to decide on a share issue and on the
granting of stock options and other special rights conferring entitlement to
shares

The AGM authorized the Board to decide on a share issue of a maximum of 797.940
shares or to grant special rights (including stock options) entitling holders to
shares as referred to in Chapter 10 Section 1 of the Companies Act, in one or
several tranches.

This authorization is proposed to be used to finance and implement any
prospective corporate acquisitions or other transactions, to implement the
company's share-based incentive plans, or for other purposes determined by the
Board.

The authorization is also proposed to grant the Board the right to decide on all
terms and conditions governing said share issue and the granting of special
rights, including the subscribers or the grantees of said special rights and the
payable consideration.

The authorization also includes the right to waive shareholders' pre-emptive
subscription rights and covers the issue of new shares and the transfer of any
shares that may be held by the company.

This authorization will be valid until April 30, 2018. This authorization shall
supersede the authorization to decide on a share issue and on the granting of
special rights giving entitlement to shares granted in the AGM of March
15, 2016.

6. Reduction in share premium reserve

The AGM decided to reduce the share premium reserve included in restricted
equity in the parent company Revenio Group Corporation's balance sheet as per
December 31, 2016 by transferring all funds, EUR 2,439,301.82 to the company's
reserve for invested non-restricted equity.

Share premium reserve is included in restricted equity, which is subject to
usage limitations. After the proposed reduction, the assets would be included in
non-restricted equity, which would permit a more flexible capital structure and
thereby more efficient use of the company's assets.

The reduction in the share premium reserve involves no compensation and does not
affect the number of company shares, shareholders' rights, or the proportional
ownership of shareholders. Entry into force of the proposed reduction requires a
public announcement and registration by Finnish Patent and Registration Office.
The Board of Directors will make decisions regarding all practicalities related
to the reduction of the share premium reserve.

Revenio Group Corporation
Board of Directors


For further information, please contact:
President & CEO Timo Hildén, tel. +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on intraocular pressure measurement technology that
has a strong patent. Revenio Group consists of, in addition to the parent
company, Icare Finland Oy which focuses on intraocular pressure measurement
technology and its fully owned subsidiary Icare USA Inc., research and
development company Revenio Research Oy and Oscare Medical Oy, in which Revenio
holds a 53.5% interest. The common denominators of Revenio's business operations
include screening, follow-up, and the global need to make cost savings through
preventive health care. Revenio seeks vigorous growth in health technology.
Revenio aims to develop even more efficient and easily adopted methods for the
early-stage detection of diseases with significance for public health. The focus
of Revenio's screening technology is on the early detection of glaucoma,
osteoporosis, skin cancer, and asthma, and the monitoring of these during the
treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating margin
for continuing operations standing at 30.1% from continuous operations. Revenio
Group Corporation is listed on Nasdaq Helsinki.




[]